BMIQ14
MCID: BDY017
MIFTS: 45

Body Mass Index Quantitative Trait Locus 14 (BMIQ14)

Categories: Bone diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 14

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 14:

Name: Body Mass Index Quantitative Trait Locus 14 56 29 13
Obesity 56 71
Obesity, Susceptibility to, Bmiq14 56
Obesity, Susceptibility to 56
Obesity Bmiq14 56
Bmiq14 56

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive

Miscellaneous:
only individuals homozygous for risk or non-risk alleles were studied


HPO:

31
body mass index quantitative trait locus 14:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 56 612460
MedGen 41 C2675914
SNOMED-CT via HPO 68 258211005
UMLS 71 C0028754

Summaries for Body Mass Index Quantitative Trait Locus 14

MalaCards based summary : Body Mass Index Quantitative Trait Locus 14, also known as obesity, is related to body mass index quantitative trait locus 11 and obesity, early-onset, with adrenal insufficiency and red hair, and has symptoms including symptoms, high weight and obesity, metabolically benign. An important gene associated with Body Mass Index Quantitative Trait Locus 14 is FTO (FTO Alpha-Ketoglutarate Dependent Dioxygenase). The drugs Oseltamivir and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and breast.

More information from OMIM: 612460

Related Diseases for Body Mass Index Quantitative Trait Locus 14

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 14 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2052)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 11 12.7
2 obesity, early-onset, with adrenal insufficiency and red hair 12.7
3 morbid obesity and spermatogenic failure 12.7
4 leptin deficiency or dysfunction 12.6
5 genetic obesity 12.6
6 obesity-hypoventilation syndrome 12.6
7 mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome 12.5
8 obesity, hyperphagia, and developmental delay 12.5
9 abdominal obesity-metabolic syndrome 1 12.5
10 spastic paraplegia, intellectual disability, nystagmus, and obesity 12.5
11 retinal dystrophy and obesity 12.5
12 abdominal obesity-metabolic syndrome 3 12.5
13 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 12.5
14 hypothalamic obesity 12.5
15 hydrocephalus obesity hypogonadism 12.4
16 x-linked intellectual disability - short stature - obesity 12.4
17 body mass index quantitative trait locus 19 12.4
18 leptin receptor deficiency 12.3
19 body mass index quantitative trait locus 20 12.3
20 abdominal obesity-metabolic syndrome quantitative trait locus 2 12.3
21 aniridia - ptosis - intellectual disability - familial obesity 12.3
22 obesity due to melanocortin 4 receptor deficiency 12.3
23 abdominal obesity-metabolic syndrome 4 12.3
24 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 12.3
25 coloboma-obesity-hypogenitalism-mental retardation syndrome 12.2
26 short stature-obesity syndrome 12.2
27 mental retardation, obesity, mandibular prognathism, and eye and skin anomalies 12.2
28 prolactin deficiency with obesity and enlarged testes 12.2
29 cohen syndrome 12.2
30 obesity due to congenital leptin resistance 12.2
31 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 12.2
32 obesity due to sim1 deficiency 12.2
33 wilson-turner x-linked mental retardation syndrome 12.2
34 syndromic obesity 12.2
35 body mass index quantitative trait locus 9 12.2
36 body mass index quantitative trait locus 12 12.2
37 body mass index quantitative trait locus 4 12.2
38 body mass index quantitative trait locus 8 12.2
39 body mass index quantitative trait locus 7 12.2
40 body mass index quantitative trait locus 18 12.2
41 midface hypoplasia, obesity, developmental delay, and neonatal hypotonia 12.2
42 mehmo syndrome 12.1
43 body mass index quantitative trait locus 10 12.1
44 proprotein convertase 1/3 deficiency 12.1
45 genetic non-syndromic obesity 12.1
46 momo syndrome 12.1
47 chops syndrome 12.1
48 genetic overgrowth/obesity syndrome 12.0
49 overgrowth/obesity syndrome 12.0
50 x-linked intellectual disability-hypogonadism-ichthyosis-obesity-short stature syndrome 12.0

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 14:



Diseases related to Body Mass Index Quantitative Trait Locus 14

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 14

Symptoms via clinical synopsis from OMIM:

56
Growth Weight:
susceptibility to obesity

Clinical features from OMIM:

612460

UMLS symptoms related to Body Mass Index Quantitative Trait Locus 14:


symptoms, high weight, obesity, metabolically benign, monogenic obesity

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 14

Drugs for Body Mass Index Quantitative Trait Locus 14 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
2
Citalopram Approved Phase 4 59729-33-8 2771
3
Enalaprilat Approved Phase 4 76420-72-9 6917719
4
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
5
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
6
Vancomycin Approved Phase 4 1404-90-6 441141 14969
7
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
8
Lixisenatide Approved Phase 4 320367-13-3
9
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
10
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
11
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
12
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
13
Ticagrelor Approved Phase 4 274693-27-5 9871419
14
Tolnaftate Approved, Investigational, Vet_approved Phase 4 2398-96-1 5510
15
Dapsone Approved, Investigational Phase 4 80-08-0 2955
16
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
17
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
18
Acetaminophen Approved Phase 4 103-90-2 1983
19
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
20
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
21
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
22
Adenosine Approved, Investigational Phase 4 58-61-7 60961
23
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
24
Metronidazole Approved Phase 4 443-48-1 4173
25
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
26
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
27
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
28
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
29
Losartan Approved Phase 4 114798-26-4 3961
30
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
31
Norepinephrine Approved Phase 4 51-41-2 439260
32
Enoxaparin Approved Phase 4 9005-49-6 772
33
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
34
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
35
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
36
Ibuprofen Approved Phase 4 15687-27-1 3672
37
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
38
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
39
Infliximab Approved Phase 4 170277-31-3
40
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
41
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
42
Racepinephrine Approved Phase 4 329-65-7 838
43
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
44
Nadroparin Approved, Investigational Phase 4
45
Tigecycline Approved Phase 4 220620-09-7 5282044
46
Memantine Approved, Investigational Phase 4 19982-08-2 4054
47
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
48
Lactulose Approved Phase 4 4618-18-2 11333
49
Ethambutol Approved Phase 4 74-55-5 3279 14052
50
Ziprasidone Approved Phase 4 146939-27-7 60854

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
2 Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Unknown status NCT02952963 Phase 4 Chenodeoxycholic Acid;Colesevelam
3 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
4 The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
5 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
6 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
7 Effects of Chenodeoxycholic Acid and Colesevelam on GLP-1 Secretion, During a Meal, After Roux-en-Y Gastric Bypass Unknown status NCT02876484 Phase 4 Colesevelam;Chenodeoxycholic Acid
8 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
9 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
10 A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity. Unknown status NCT01864187 Phase 4 Dexmedetomidine
11 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
12 Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
13 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
14 Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women Unknown status NCT01320917 Phase 4
15 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
16 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity: a Prospective,Controlled, Randomized, Multicentrique Study. Unknown status NCT01550601 Phase 4
17 Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial Unknown status NCT01878994 Phase 4
18 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
19 Children's Healthy Living Program for Remote Underserved Minority Populations in the Pacific Region Unknown status NCT01881373 Phase 4
20 Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery. Unknown status NCT02295150 Phase 4 Nadroparin
21 Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) Unknown status NCT02055014 Phase 4 Liraglutide
22 Beijing Chao-yang Hospital, Capital Medical University Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
23 Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade Unknown status NCT02118844 Phase 4 rocuronium
24 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
25 Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities Unknown status NCT02050477 Phase 4
26 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
27 Prospective, Randomized, Double - Blind, Placebo Controlled Trial of Dietary Modification in Conjunction With Probiotic Therapy on Clinical and Endocrinological Parameters as Well as Body Composition in Women With Polycystic Ovary Syndrome Unknown status NCT03325023 Phase 4
28 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
29 Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
30 International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
31 Influence of Erythromycin on ad Libitum Food Intake and the Evaluation of Motilin in Food Timing in Healthy Volunteers and Patients Unknown status NCT03024879 Phase 4 Erythromycin;Saline
32 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
33 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4 Hydroxocobalamin;FitForMe vitamin B12
34 What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone(BLOOD STUDY) Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
35 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
36 Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
37 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Unknown status NCT02374632 Phase 4
38 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
39 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
40 What is the Effects of Prokinetic Drug on the Blood Glucose in Type 2 Diabetes Patients: Mosapride Comparing Placebo Unknown status NCT02606617 Phase 4 Mosapride;Placebo
41 Efficacy of Vitamin D Supplementation in Obese Children Unknown status NCT02956408 Phase 4
42 The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men Unknown status NCT03012113 Phase 4 Mirabegron;Placebo Oral Capsule
43 BARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery Unknown status NCT03341429 Phase 4 Liraglutide Pen Injector [Saxenda];Placebo
44 Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity in Human Adults Unknown status NCT02524184 Phase 4 sildenafil;placebo
45 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
46 Influence of the Aromatase Inhibitor Letrozole on Heart and Liver Function in Obese Men Unknown status NCT02097680 Phase 4 Letrozole;Placebo
47 Determining the Minimal Effective Volume (MEAV95) for Interscalene Brachial Plexus Block for Surgical Anesthesia Unknown status NCT01703130 Phase 4
48 The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance Unknown status NCT02502344 Phase 4 Metformin
49 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
50 Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan Unknown status NCT01271374 Phase 4 amlodipine and olmesartan;losartan and HCTZ

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 14

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Benzphetamine
Benzphetamine hydrochloride
Dexfenfluramine
Dexfenfluramine Hydrochloride
Diethylpropion
Diethylpropion Hydrochloride
Fenfluramine
Fenfluramine Hydrochloride
lorcaserin
lorcaserin hydrochloride
Mazindol
Methamphetamine
orlistat
phendimetrazine
PHENDIMETRAZINE HYDROCHLORIDE
phendimetrazine tartrate
Phenmetrazine
Phenmetrazine Hydrochloride
Phentermine
Phentermine Hydrochloride
PHENTERMINE RESIN
Phenylpropanolamine
Phenylpropanolamine Hydrochloride
sibutramine
SIBUTRAMINE HYDROCHLORIDE

Genetic Tests for Body Mass Index Quantitative Trait Locus 14

Genetic tests related to Body Mass Index Quantitative Trait Locus 14:

# Genetic test Affiliating Genes
1 Body Mass Index Quantitative Trait Locus 14 29

Anatomical Context for Body Mass Index Quantitative Trait Locus 14

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 14:

40
Liver, Heart, Breast, Brain, Testes, Kidney, Bone

Publications for Body Mass Index Quantitative Trait Locus 14

Articles related to Body Mass Index Quantitative Trait Locus 14:

(show top 50) (show all 30012)
# Title Authors PMID Year
1
FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. 61 56
26287746 2015
2
Obesity, FTO gene variant, and energy intake in children. 61 56
19357416 2009
3
Variation in FTO contributes to childhood obesity and severe adult obesity. 61 56
17496892 2007
4
FTO genotype is associated with phenotypic variability of body mass index. 56
22982992 2012
5
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. 56
21706003 2011
6
A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. 56
20404173 2010
7
Life course variations in the associations between FTO and MC4R gene variants and body size. 56
19880856 2010
8
Replication and extension of genome-wide association study results for obesity in 4923 adults from northern Sweden. 56
19164386 2009
9
Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. 56
19151714 2009
10
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. 56
19079261 2009
11
An obesity-associated FTO gene variant and increased energy intake in children. 56
19073975 2008
12
Obesity associated genetic variation in FTO is associated with diminished satiety. 56
18583465 2008
13
Common variants near MC4R are associated with fat mass, weight and risk of obesity. 56
18454148 2008
14
A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. 56
17434869 2007
15
FTO polymorphisms in oceanic populations. 56
17928949 2007
16
Obesity in midlife: lifestyle and dietary strategies. 61
31576760 2020
17
Associations between obesity and neighborhood socioeconomic status: Variations by gender and family income status. 61
31890849 2020
18
Adolescent stress: A predictor of dieting behaviors in youth with overweight/obesity. 61
31870936 2020
19
Age of obesity onset, cumulative obesity exposure over early adulthood and risk of type 2 diabetes. 61
31858184 2020
20
Ripple Effects of the Communities Preventing Childhood Obesity Project. 61
30117342 2020
21
More precise prevalence of overweight and obesity. 61
31762168 2020
22
Obesity: A preventable, treatable, but relapsing disease. 61
31864969 2020
23
Diabetes Mellitus, Obesity, and the Placenta. 61
32008672 2020
24
Leptin, obesity, and response to ketamine. 61
31672525 2020
25
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. 61
31733195 2020
26
The relationship between cortisol and IGF-I influences metabolic alteration in pediatric overweight and obesity. 61
31863690 2020
27
The effect of interaction between parity, gestational diabetes, and pregravid obesity on the incidence of preeclampsia. 61
30081684 2020
28
Re: Association between enuresis and obesity in children with primary monosymptomatic nocturnal enuresis. 61
32022532 2020
29
Words with weight: The construction of obesity in eating disorders research. 61
29992834 2020
30
Obesity in youth and adults with intellectual disability in Europe and Eurasia. 61
31482623 2020
31
Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity. 61
31845423 2020
32
Pediatric obesity treatment, self-esteem, and body image: A systematic review with meta-analysis. 61
32020780 2020
33
Associations of nitric oxide with obesity and psychological traits among children and adolescents in Taiwan. 61
31786830 2020
34
Metabolically healthy general and abdominal obesity are associated with increased risk of hypertension. 61
31791429 2020
35
The Role of Obesity in Iatrogenic Encephaloceles of the Temporal Bone. 61
31851068 2020
36
Chemokines in human obesity. 61
31865065 2020
37
Dietary management of blood glucose in medical critically ill patients with overweight/obesity. 61
32004236 2020
38
Obesity-Induced Regulator of Calcineurin 1 Overexpression Leads to β-Cell Failure Through Mitophagy Pathway Inhibition. 61
31822118 2020
39
Assessing the acceptability of an adapted preschool obesity prevention programme: ToyBox-Scotland. 61
31856335 2020
40
Guidelines for the management of pregnant women with obesity: A systematic review. 61
31943650 2020
41
Obesity and dental caries in early childhood: A systematic review and meta-analyses. 61
31721413 2020
42
A scoping review on economic globalization in relation to the obesity epidemic. 61
31724312 2020
43
Depression subtypes and obesity in adults: A systematic review and meta-analysis. 61
31724325 2020
44
Gut microbiome and its role in obesity and insulin resistance. 61
31087391 2020
45
Association of Serum Zinc Levels in Overweight and Obesity. 61
32020525 2020
46
Aging, Diabetes, Obesity, and Cognitive Decline: A Population-Based Study. 61
32020605 2020
47
Obesity and ageing: Two sides of the same coin. 61
32020741 2020
48
Review: Diabetes, Obesity, and Cancer-Pathophysiology and Clinical Implications. 61
31722374 2020
49
Clinical encounters about obesity: Systematic review of patients' perspectives. 61
31793217 2020
50
Obesity in adolescents and cancer risk: causal relationship or epiphenomenon? 61
32027850 2020

Variations for Body Mass Index Quantitative Trait Locus 14

Expression for Body Mass Index Quantitative Trait Locus 14

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 14.

Pathways for Body Mass Index Quantitative Trait Locus 14

GO Terms for Body Mass Index Quantitative Trait Locus 14

Sources for Body Mass Index Quantitative Trait Locus 14

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....